Scientists from Genzyme Corporation and ISIS Pharmaceuticals Publish Paper Showing Antisense Oligonucleoties (ASOs) Ameliorate Symptoms in a Severe Mouse Model of Spinal Muscular Atrophy
Science Translational Medicine (via FSMA) | March 4, 2011
It was reported in the journal Science Translational Medicine that ASOs designed to correct splicing of the SMN2 gene improve symptoms in a severe mouse model of Spinal Muscular Atrophy when delivered directly to the CNS.
Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder caused by mutations in the SMN1 gene that result in a deficiency of SMN protein. One approach to treat SMA is to use antisense oligonucleotides (ASOs) to redirect the splicing of the SMN2 gene to boost production of functional SMN.
Click HERE or on the image below to read more…
SMAHeadlines.com 
I have fun with, lead to I found exactly what I was looking for.
You have ended my four day lengthy hunt! God Bless
you man. Have a nice day. Bye
Hi there to every body, it’s my first visit of this weblog; this webpage
consists of amazing and genuinely excellent stuff for
readers.
Heya this is kinda of off topic but I was wondering if blogs use WYSIWYG editors or if you have to manually code with HTML. I’m starting a blog soon but have no coding expertise so I wanted to get advice from someone with experience. Any help would be enormously appreciated!|
We are a bunch of volunteers and opening a brand new scheme in our community.
Your web site provided us with helpful information to work on. You’ve performed an impressive activity and our whole community will be grateful to you.